AlphaCore Capital LLC Buys 498 Shares of Eli Lilly and Company $LLY

AlphaCore Capital LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 8.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 6,607 shares of the company’s stock after acquiring an additional 498 shares during the period. AlphaCore Capital LLC’s holdings in Eli Lilly and Company were worth $5,041,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Eli Lilly and Company by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company’s stock valued at $61,771,785,000 after buying an additional 551,659 shares in the last quarter. Laurel Wealth Advisors LLC raised its stake in shares of Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after acquiring an additional 11,537,661 shares in the last quarter. Norges Bank purchased a new position in shares of Eli Lilly and Company during the second quarter worth approximately $8,827,714,000. Jennison Associates LLC lifted its holdings in shares of Eli Lilly and Company by 4.3% in the 2nd quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock worth $4,246,596,000 after acquiring an additional 226,620 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Eli Lilly and Company by 2.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock valued at $4,178,010,000 after purchasing an additional 103,119 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

LLY stock opened at $1,030.30 on Thursday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The firm has a market capitalization of $971.95 billion, a price-to-earnings ratio of 44.89, a PEG ratio of 1.21 and a beta of 0.39. The firm has a 50 day moving average price of $1,054.25 and a 200-day moving average price of $924.46.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter in the previous year, the business earned $5.32 earnings per share. The firm’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is 30.15%.

Analysts Set New Price Targets

LLY has been the topic of several analyst reports. Argus lifted their price objective on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a report on Monday, February 9th. CICC Research raised their target price on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a report on Wednesday, February 11th. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 31st. HSBC reiterated a “hold” rating and issued a $1,070.00 price objective on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Finally, JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,229.33.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s oral obesity candidate completed an early trial stage, sharpening investor focus on a potential oral GLP‑1/GIP pathway competitor to injectables — a major long‑term revenue lever if translated to late‑stage success. TipRanks: Oral obesity trial completion
• Positive Sentiment: Positive Phase 3 VIVID‑2 open‑label extension results for Omvoh (mirikizumab) bolster Lilly’s non‑GLP‑1 pipeline (Crohn’s/UC), reducing single‑product concentration risk and adding near‑term commercial optionality. Yahoo Finance: VIVID‑2 results
• Positive Sentiment: Analysts have largely stayed constructive: Truist reaffirmed a buy rating and Goldman/Goldman‑coverage notes (and price targets) remain supportive, which can limit downside from headline volatility. MarketScreener: Truist reaffirms buy
• Neutral Sentiment: Bank of America and other firms argue Novo’s announced list‑price cuts are unlikely to meaningfully dent U.S. GLP‑1 volumes for rivals in the near term, suggesting the sector pricing move may be more tactical than market‑eroding. That view helps explain why some investors see the price cut as contained risk rather than an existential threat to Lilly’s sales. Yahoo Finance: BofA sees limited impact
• Neutral Sentiment: Macro/sector coverage pieces and long‑term growth analyses highlight that Lilly’s GLP‑1 blockbusters (Mounjaro/Zepbound) drove a majority of recent revenue growth, keeping the long‑term story intact even as short‑term headlines create choppiness. Zacks: GLP‑1 revenue drivers
• Negative Sentiment: Novo Nordisk announced plans to cut U.S. list prices for Wegovy/Ozempic by up to ~50% starting in 2027 — a direct sector shock that triggered investor worry about pricing pressure, broader margin implications and potential share‑loss dynamics across GLP‑1 makers. That news is the primary reason for today’s downward pressure. Yahoo Finance: Novo halves US price
• Negative Sentiment: Several outlets flagged that investors reacted nervously — and some short‑term selloffs followed — after the Novo pricing announcement and prior trial headlines; that volatility can amplify intraday declines despite Lilly’s strong fundamentals. Fool: Why LLY slumped

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.